|1.||Heller, Axel R: 2 articles (08/2010 - 08/2003)|
|2.||Koch, Thea: 2 articles (08/2010 - 08/2003)|
|3.||Ducharme, Anique: 1 article (01/2015)|
|4.||Sayat, Guliz: 1 article (01/2015)|
|5.||Neagoe, Paul-Eduard: 1 article (01/2015)|
|6.||Carrier, Michel: 1 article (01/2015)|
|7.||Esendagli, Gunes: 1 article (01/2015)|
|8.||Talim, Beril: 1 article (01/2015)|
|9.||White, Michel: 1 article (01/2015)|
|10.||Karabudak, Rana: 1 article (01/2015)|
01/01/2015 - "Concomitantly to plasma assessment, circulating neutrophils were isolated, purified and stimulated by vehicle (PBS), N-formyl-Met-Leu-Phe (fMLP, 10(-7) M), bacterial lipopolysaccharide (LPS, 1 μg/mL), or tumour necrosis factor alpha (TNF-α, 10 ng/mL). "
03/01/1997 - "In intact PMNs primed with tumour necrosis factor alpha before stimulation with N-formyl-Met-Leu-Phe, AA release and metabolism and PAF formation increased in parallel with enhanced PA and DG formation, and inhibition of PA and DG production led to a decrease in both AA release and PAF accumulation. "
04/01/1995 - "When patient PMN were cultured in the presence of 1000 U/mL IFN-alpha, enhancement of the formyl-methionyl-leucyl-phenylalanine induced O2- generation following priming with tissue necrosis factor-alpha was observed. "
05/01/1999 - "Human neutrophils, incubated with Cr51-labelled B lymphoblastoid Raji cells in the presence of the anti-target monoclonal antibody (mAb) Lym-1 plus formyl-methionyl-leucyl-phenylalanine (FMLP) or tumour necrosis factor alpha (TNF-alpha), were found to induce significant C51 release, i.e. "
12/01/2011 - "Tumour necrosis factor α and formyl-Met-Leu-Phe (fMLP) treatment of non-primed neutrophils and treatment of primed neutrophils with anti-PR3 ANCA IgG resulted in a significant increase in surface expression of BLyS within 30 min which returned to basal levels by 2 h. "
04/01/2001 - "The early stages of inflammation in response to topical suffusion of mesentery tissue with formyl-methionyl-leucyl-phenylalanine (FMLP) were monitored using intravital microscopy. "
09/01/1989 - "Formyl-methionyl-leucyl-phenylalanine-induced intestinal inflammation."
04/01/2008 - "When formyl-Met-Leu-Phe-OH (fMLP)-mediated acute inflammation was produced in the lymph nodes, the lymph outflow rate through the node was significantly decreased. "
07/01/2004 - "The decreased inflammation correlated with lower chemotaxis/chemokinesis of peripheral blood mononuclear cells (PBMC) toward formyl-methionyl-leucyl-phenylalanine and monocyte chemoattractant protein-1 without affecting the density of their respective receptors. "
06/01/1995 - "Neutrophil mediated ileal inflammation induced by formyl-methionyl-leucyl-phenylalanine (fMLP) perfusion was evaluated by measuring macromolecular uptake of radiolabelled dextran (MW 70,000) and changes in mucosal neutrophil infiltration. "
|3.||Chronic Obstructive Pulmonary Disease (COPD)
05/01/2003 - "The purpose of this study was to explore the relationship between cigarette smoking and COPD on the number of formyl methionyl leucyl phenylalanine (FMLP) receptors on peripheral neutrophils. "
01/01/2012 - "Neutrophils were isolated from 15 severe, early-onset COPD patients and 15 age-matched healthy subjects and stimulated with N-formyl-Met-Leu-Phe (fMLP) in the presence or absence of NAC (10 μM to 10 mM). "
05/01/2011 - "COPD neutrophils moved with greater speed than cells from either control group but with reduced migratory accuracy, in the presence of IL-8, growth-related oncogene α, formyl-methionyl-leucyl-phenylalanine, and sputum. "
03/01/2007 - "In addition, chemotactic responses to N-formyl-Met-Leu-Phe (fMLP) and interleukin-8 (IL-8/CXCL8) were studied using neutrophils from healthy subjects and subjects with COPD. "
|4.||Psoriasis (Pustulosis Palmaris et Plantaris)
06/01/2004 - "The aim of our study was expression of CD11b/CD18 molecules without and after stimulation by fMLP (formyl-Met-Leu-Phe) in patients with psoriasis vulgaris treated by PUVA. "
11/01/1987 - "Although the number of plasma membrane receptor for chemotactic peptides in the nonstimulated neutrophils was not altered in psoriasis, the receptor up-regulation induced by preincubation of the cells with 1-10 nM of nonlabeled N-formyl-Met-Leu-Phe at 37 degrees C was reduced when measured by subsequent fluoresceinated hexapeptide uptake at 0 degree C. "
01/01/1987 - "In the active phase of pustular psoriasis, the neutrophil chemiluminescence response to the chemotactic peptide f-met-leu-phe and to phorbol myristate acetate was enhanced and correlated to the development of pustules, whereas cells from psoriasis vulgaris patients showed normal chemiluminescence response. "
03/01/2014 - "In the present study, we examined the polarization of differentiated human neutrophil-like HL-60 (dHL-60) cells exposed to hypoxia (3% O2) and the results demonstrated that the percentage of polarized cells following exposure to an N-formyl-Met-Leu-Phe (fMLP) gradient in the Zigmond chamber was increased. "
07/01/1999 - "Hypoxia also inhibited the chemotactic response to macrophage inflammatory protein-1alpha, RANTES and the chemoattractant N-formyl-met-leu-phe, but hypoxic cells were still able to phagocytose opsonized red blood cells. "
08/01/1986 - "To confirm this in vivo, we studied the ability of ibuprofen i.v. pretreatment to reverse the transcutaneous hypoxia induced by i.v. infusion of 1 nmol/kg of formyl-methionyl-leucyl-phenylalanine. "
|3.||Interleukin-8 (Interleukin 8)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Reactive Oxygen Species (Oxygen Radicals)
|8.||Hydrogen Peroxide (Hydroperoxide)